Loading…
Phathom Pharmaceuticals, Inc. is projected to rise to $9.83 by 2027, a +12% move from its current price of $8.75. PHAT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $8.34 | $8.74 | $9.17 | -0.06% |
| Aug 3 | $8.17 | $8.74 | $9.34 | -0.13% |
| Aug 4 | $8.05 | $8.73 | $9.48 | -0.19% |
| Aug 5 | $7.94 | $8.73 | $9.59 | -0.25% |
| Aug 6 | $7.85 | $8.72 | $9.70 | -0.31% |
| Aug 7 | $7.76 | $8.72 | $9.79 | -0.38% |
| Aug 8 | $7.69 | $8.71 | $9.87 | -0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.69 | $8.71 | $9.87 | -0.44% |
| Week 2 | $7.27 | $8.67 | $10.35 | -0.87% |
| Week 3 | $6.95 | $8.64 | $10.72 | -1.31% |
| Week 4 | $6.69 | $8.60 | $11.04 | -1.74% |
| Week 5 | $6.47 | $8.56 | $11.32 | -2.17% |
| Week 6 | $6.27 | $8.52 | $11.58 | -2.60% |
| Week 7 | $6.09 | $8.49 | $11.81 | -3.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Phathom Pharmaceuticals, Inc. (PHAT) is a healthcare/biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; VOQUEZNA Triple Pak and VOQUEZNA Dual Pak have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. trades in the healthcare/biopharma space and operates with a focus on GI diseases. The stock is currently priced and tracked with a market valuation, and it sits at a specific rank by market cap.
The current price, market cap, and rank provide context for its market position. Forecast data outline a multi-year price pathway with neutral near-term momentum and bullish longer-term potential.
A major floor 29.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 44.1% above — a clean break opens room to run.
A major ceiling 58.8% above — clearing it would confirm fresh momentum.
Key PHAT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.61 | Sell | $10.09 | Sell |
| MA 10 | $10.97 | Sell | $10.64 | Sell |
| MA 20 | $11.22 | Sell | $10.91 | Sell |
| MA 50 | $10.80 | Sell | $11.07 | Sell |
| MA 100 | $11.25 | Sell | $11.39 | Sell |
| MA 200 | $12.66 | Sell | $11.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.22 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -257.14 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | -20.81 | Sell |
| Bollinger %B (20,2) | -0.18 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 21.93 | Buy |
| Momentum (10) | -2.19 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 9.75 | Sell |
| ADX (14) | 14.43 | Neutral |
| ATR (14) | 0.45 | Info |
The 30-day technical picture is bearish. RSI(14) stands at 30, with the stock trading below both the SMA50 and SMA200, which are $10.85 and $12.68 respectively. Immediate support is at $9.03 and resistance at $12.61. The 30-day price range spans from $6.57 to $12.42, highlighting a wide, choppy short-term path.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.75 | $8.75 | $10.51 | 0% | Neutral | |
| $7.32 | $9.83 | $14.22 | +12% | Neutral | |
| $7.49 | $10.61 | $16.28 | +21% | Bullish | |
| $9.15 | $13.55 | $21.76 | +55% | Bullish | |
| $10.01 | $15.44 | $25.73 | +76% | Bullish | |
| $8.88 | $14.21 | $24.45 | +62% | Bullish | |
| $9.21 | $15.27 | $27.03 | +75% | Bullish | |
| $8.54 | $14.65 | $26.61 | +67% | Bullish | |
| $8.56 | $15.17 | $28.21 | +73% | Bullish | |
| $12.34 | $22.58 | $42.88 | +158% | Bullish | |
| $11.39 | $24.26 | $50.33 | +177% | Bullish | |
| $23.46 | $52.14 | $119.91 | +496% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.75 | $8.75 | $10.39 | +0.00% |
| September 2026 | $7.11 | $8.60 | $10.82 | -1.70% |
| October 2026 | $6.75 | $8.26 | $10.58 | -3.93% |
| November 2026 | $6.26 | $7.74 | $10.05 | -6.36% |
| December 2026 | $6.40 | $7.99 | $10.51 | +3.21% |
Click any year to see its month-by-month PHAT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PHAT could reach as high as $10.51, with a base case around $8.75 and support toward $8.75 — roughly 0% from $8.75. Price action looks broadly range-bound.
Expect PHAT to range from $7.32 to $14.22 through 2027. The $9.83 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
The PHAT price prediction for 2028 points to an average of $10.61 (low $7.49, high $16.28) — a potential gain of +21% on today's $8.75. Momentum favours further upside here.
In 2029, PHAT is projected to trade between $9.15 and $21.76, averaging $13.55 — a potential gain of +55% from today's $8.75. That is up +28% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Phathom Pharmaceuticals, Inc.'s 2030 outlook centres on $15.44, within a $10.01 to $25.73 range. That is up +14% on the projected 2029 average. That marks a +76% change versus current levels. Momentum favours further upside here.
By 2031, PHAT could reach as high as $24.45, with a base case around $14.21 and support toward $8.88 — roughly +62% from $8.75. Buyers look set to stay in control over this stretch.
Expect PHAT to range from $9.21 to $27.03 through 2032. The $15.27 average target implies a +75% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The PHAT price prediction for 2033 points to an average of $14.65 (low $8.54, high $26.61) — a potential gain of +67% on today's $8.75. Buyers look set to stay in control over this stretch.
In 2034, PHAT is projected to trade between $8.56 and $28.21, averaging $15.17 — a potential gain of +73% from today's $8.75. That is up +4% on the projected 2033 average. Momentum favours further upside here.
Phathom Pharmaceuticals, Inc.'s 2035 outlook centres on $22.58, within a $12.34 to $42.88 range. That is up +49% on the projected 2034 average. That marks a +158% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PHAT could reach as high as $50.33, with a base case around $24.26 and support toward $11.39 — roughly +177% from $8.75. Momentum favours further upside here.
Expect PHAT to range from $23.46 to $119.91 through 2050. The $52.14 average target implies a +496% move from current prices. That is up +115% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAT today (≈ 114.285714 PHAT) could be worth
$5,958.46
+$4,958.46 (+496%) by 2050 · US Dollar
Based on the average projected PHAT price of $52.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHATwould be worth at today's price.
$1,000 invested in PHAT on Jul 31, 2025 (≈ 117.096019 PHAT) would be worth
$1,024.59
+$24.59 (+2.5%) today · 1.02× · US Dollar
Based on a PHAT entry price of $8.54 vs. today's $8.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.44 | $764.86 | -23.5% |
| 1 month ago | $10.53 | $830.56 | -16.9% |
| 3 months ago | $12.01 | $728.56 | -27.1% |
| 6 months ago | $13.81 | $633.6 | -36.6% |
| 1 year ago | $8.54 | $1,024.59 | +2.5% |
| All time (5.0y) ago | $31.95 | $273.87 | -72.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAT forecast.
Our base-case forecast reaches $18.00 around 2035.
Implied market cap at $18.00: $1.46B
The multi-year forecast shows a bullish trajectory beginning in 2029, with the average price rising from $13.86 in 2029 to $52.29 in 2050 and an overall return profile that expands into the high hundreds of percent by 2050. Notable mid-term milestones include 2029 with an avg of $13.86 and ROI of 53.5, 2030 with an avg of $15.78 and ROI of 74.7, and 2035 with an avg of $22.86 and ROI of 153.1. The forecast continues to 2040 with an avg of $24.21 and ROI of 168.2, and culminates in 2050 with an avg of $52.29 and ROI of 479.1, with a max forecast of $120.28.
These figures point to a sustained bullish outlook across the later years, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows min $10.15, avg $15.78, max $26.47 with a ROI of 74.7% and a bullish sentiment.
The forecast turns bullish from 2029 onward, with rising average prices and ROIs—2030 avg $15.78 (ROI 74.7%), 2035 avg $22.86 (ROI 153.1%), and 2050 avg $52.29 (ROI 479.1%), though near-term sentiment is Neutral and results are not guaranteed.
Yes—the 2050 max forecast is $120.28, indicating a potential to exceed $100 in the long term, with 2050 avg $52.29 and ROI of 479.1%.
For 2026, the min is $9.03, the avg is $9.03, and the max is $10.85, with Neutral sentiment.
Current price is $9.03 and market capitalization is $730.54M; the stock ranks 2580.
Phathom Pharmaceuticals, Inc. Community Discussion
0Share your Phathom Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.